Abstract:These findings suggest that clinical parameters and biomarkers have a role in predicting the radiological severity of PE. These data support the need for further studies of risk stratification in patients presenting with acute PE.
“…According to Ghaye et al (10) and van der Meer et al (9), RV/LV ratio is a strong predictor of the severity of PE and patient outcome. This is in contrast to the studies of Araoz et al (11) and Jeebun et al (15), in which no association between the RV/LV ratio and death was reported. Similarly, in our study, RV/LV ratio did not predict mortality at 30-day followup.…”
Section: Discussioncontrasting
confidence: 95%
“…The strong correlation between troponin I levels and both PAOI and RV/LV ratio has recently been emphasized by Shokoohi et al (14) and Jeebun et al (15). Consistent with these studies, we also found a significant but low correlation between troponin I levels and both PAOI and RV/LV ratio.…”
“…According to Ghaye et al (10) and van der Meer et al (9), RV/LV ratio is a strong predictor of the severity of PE and patient outcome. This is in contrast to the studies of Araoz et al (11) and Jeebun et al (15), in which no association between the RV/LV ratio and death was reported. Similarly, in our study, RV/LV ratio did not predict mortality at 30-day followup.…”
Section: Discussioncontrasting
confidence: 95%
“…The strong correlation between troponin I levels and both PAOI and RV/LV ratio has recently been emphasized by Shokoohi et al (14) and Jeebun et al (15). Consistent with these studies, we also found a significant but low correlation between troponin I levels and both PAOI and RV/LV ratio.…”
“…The level of d-dimers has been shown to correlate with right heart dysfunction and clot burden as well as to be a negative outcome predictor, since short and long term survival after acute PE is limited with increasing d-dimer levels [25][26][27][28][29][30]. However, keeping in mind the low specificity of this test, the mean d-dimer level was also slightly elevated in the control group without PE, but it was significantly lower than in patients with PE.…”
“…15 studies were initially excluded [10,19,20,22,26,31,33,35,38,39,41,43,46,50,52]. For six of them, the inclusion in the analysis was possible following contact with the authors [22,35,38,39,43,52].…”
Section: Meta-analysis Of Ct Assessed Right Ventricle Dilationmentioning
The aim of this study was to evaluate whether right ventricle dilation at computed tomography (CT) angiography can be used to assess the risk of death in patients with acute pulmonary embolism.Medline and EMBASE were searched up to April 30, 2013. Studies reporting on the association between right ventricle dilation (right-to-left ventricle diameter) or dysfunction (inter-ventricular septal bowing) at CT angiography and death at 30 days, as well as at 3 months in patients with acute pulmonary embolism, were included in a systematic review and meta-analysis.CT-detected right ventricle dilation was associated with an increased 30 day-mortality in all-comers with pulmonary embolism (OR 2.08 (95% CI 1.63-2.66); p,0.00001) and in haemodynamically stable patients (OR 1.64 (95% CI 1.06-2.52); p50.03), as well as with death due to pulmonary embolism (OR 7.35 (95% CI 3.59-15.09); p,0.00001). An association between right ventricle dilation and 3-month mortality was also observed (OR 4.65 (95% CI 1.79-12.07); p50.002).Right-to-left ventricle dilation as assessed by CT angiography can be used to evaluate risk of death in allcomers with pulmonary embolism and in haemodynamically stable patients. @ERSpublications Multidetector CT can be used to assess short-term risk of death in patients with acute pulmonary embolism
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.